Zum Inhalt springen
Home » First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

– OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis